Nearly six of ten Americans will develop kidney disease in their lifetime, according to a new analysis published in the American Journal of Kidney Diseases. In comparison, lifetime risk of diabetes, heart attack and invasive cancer is approximately four in ten.
As a result of this and previous studies, the National Kidney Foundation is calling on healthcare professionals to screen patients in specific high-risk groups for kidney disease – those age 60 or older and those with high blood pressure or diabetes – by adding a simple urine albumin test for kidney damage to annual physical examinations.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62772-national-kidney-foundation-study-screening-for-disease
Philips Respironics, a unit of Royal Philips (NYSE: PHG, AEX: PHI) and a pioneer in science-based sleep solutions, today announces a significant advancement in sleep therapy with the commercial release of a first of its kind minimal contact nasal mask – Wisp. Designed to fit more than 98% of sleep apnea patients, Wisp brings distinctive styling and patented technology for a better overall mask experience that may improve patient compliance.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62230-philips-respironics-announces-advancement-in-sleep-therapy-with-wisp
Eisai Inc. announced today that BELVIQ (pronounced BEL-VEEK) will be available to eligible patients by prescription in the United States beginning June 11.
BELVIQ was approved by the U.S. Food and Drug Administration on June 27, 2012 to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults who have a body mass index (BMI) of 30 kg/m² or greater (obese), or BMI of 27 kg/m² or greater (overweight) with at least one weight-related medical condition such as high blood pressure, high cholesterol, or type 2 diabetes. It is not known if BELVIQ is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products, nor is it known if BELVIQ changes your risk of heart problems or stroke, or of death due to heart problems or stroke.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/60316-eisai-belviq-civ-chronic-weight-management-tablets-for-overweight-adults
Diabetes experts met and determined that some self-monitoring blood glucose (SMBG) systems, despite meeting accuracy standards at the time of U.S. Food and Drug Administration (FDA) clearance, fail to consistently meet accuracy standards once on the market, potentially putting patient health at risk. In a public meeting convened by the Diabetes Technology Society on May 21, 2013, in Arlington, Virginia, leading academic clinicians, clinical chemists, medical device experts, patient advocates and FDA representatives reviewed a growing body of peer-reviewed research demonstrating that the performance of some blood glucose monitors on the market may not be meeting accuracy standards.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/61870-diabetes-technology-society-inaccurate-blood-glucose-monitors-risky
The number of gout patients is rising, with an estimated 8.3 million American adults diagnosed with gout—but only 10 percent of them are being properly treated, according to the Gout & Uric Acid Education Society. To heighten awareness and knowledge about gout and to lead to earlier diagnosis and treatment, the society has released two new comprehensive kits to educate patients and provide consistent information for medical professionals. The release of the Take a Stand on Gout Patient Education Kit and Medical Professional Information Kit coincides with Gout Awareness Day, an annual commemoration on May 22 to call attention to the growing incidence of gout and to enhance knowledge so as to improve patient outcomes. Both kits provide new, substantial information about gout from specialists, who treat gout patients every day.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61805-gout-uric-acid-education-society-take-a-stand-on-gout-new-information-kits
The following video has been edited and taken from the show aired May 8, 2013. 520,000 people living with AIDS in Thailand . The number is growing and hundreds die in pain everyday . The majority of these patients can not afford treatment since they are poor. Some HIV people just got kicked out of their houses . Thousands of them were dumped out of their family's cars in front of this temple. It still happens everyday. The place called
In a revolutionary treatment for early-onset scoliosis (EOS), a team of surgeons implanted adjustable growing rods in two children from California. The pioneering surgeries — the first ever in the United States — were performed on May 7th at Rady Children’s Hospital in San Diego. The Food and Drug Administration (FDA) granted Compassionate Use approval to use the MAGEC™ (MAGnetic Expansion Control) System, developed by Ellipse Technologies, Inc., for these two patients.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61604-rady-children-s-hospital-san-diego-ellipse-magec-early-onset-scoliosis-eos
Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61338-raptor-pharmaceutical-procysbi-fda-approval-nephropathic-cystinosis
The Bonnie J. Addario Lung Cancer Foundation invites you to join The Living Room, a lively and interactive online support group for those who are directly and indirectly affected by lung cancer. The April Living Room will feature a patient-focused program, titled “Sharing My Personal Journey.” There’s no guest speaker this month, just stories and experiences from patients and family who can offer hope to others.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56176-bjalcf-the-living-room-online-support-group-sharing-my-personal-journey
The CVS Caremark Charitable Trust, a private foundation created by CVS Caremark Corporation (NYSE: CVS) today announced the recipients of the “Innovations in Community Health” grants, which have been awarded to community health centers nationwide through a partnership with the National Association of Community Health Centers (NACHC). The grants will help community health centers increase access to quality health care and produce better health outcomes while reducing costs for patients and healthcare systems.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61405-cvs-caremark-charitable-trust-awards-21-innovations-in-community-health
New research has revealed that the use of Antimicrobial Copper surfaces in hospital rooms can reduce the number of healthcare-acquired infections (HAIs) by 58% as compared to patients treated in Intensive Care Units with non-copper touch surfaces. In the United States, 1 out of every 20 hospital patients develops an HAI, resulting in an estimated 100,000 deaths per year. Although numerous strategies have been developed to decrease these infections, Antimicrobial Copper is the only strategy that works continuously, has been scientifically proven to be effective and doesn’t depend on human behavior, according to a recently published study in the SHEA Journal of Infection Control and Hospital Epidemiology.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61120-antimicrobial-copper-surfaces-reduce-healthcare-acquired-infections
Crosstex International, a subsidiary of Cantel Medical Corp. (NYSE:CMN), and Prestige Ameritech, the only two major U.S.-based medical mask manufacturers have joined forces to bring attention to a glaring void in public health research and policy – that, if addressed, has the potential to more quickly provide a simple, effective tool to mitigate the spread of influenza and other respiratory borne viruses. The awareness campaign comes in response to a new study, “ Exposure to Influenza Virus Aerosols During Routine Patient Care,” published in The Journal of Infectious Diseases, showing that influenza viruses may spread as far as six feet from a person coughing or sneezing, and that some people, referred to as “super spreaders,” may be more likely to spread the virus. The study, supported by the Department of Health and Human Services with a $600,000 research grant, pointed specifically to concerns for healthcare workers being exposed to coughs from sick patients. Yet government research and policy continues to overlook face masks as a feasible protection measure for both the healthcare industry and the general public.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60417-cantel-medical-fitted-mask-infectious-disease-control-public-health-policy
